Unique ID issued by UMIN | UMIN000053525 |
---|---|
Receipt number | R000061087 |
Scientific Title | Study to Determine the Effects of Fermented Milk Drink on activated CD4+ T cells in Peripheral Blood Mononuclear Cells. |
Date of disclosure of the study information | 2024/02/06 |
Last modified on | 2024/08/05 11:14:09 |
Study to Determine the Effects of Fermented Milk Drink on activated CD4+ T cells in Peripheral Blood Mononuclear Cells.
Study to Determine the Effects of Fermented Milk Drink on activated CD4+ T cells in Peripheral Blood Mononuclear Cells.
Study to Determine the Effects of Fermented Milk Drink on activated CD4+ T cells in Peripheral Blood Mononuclear Cells.
Study to Determine the Effects of Fermented Milk Drink on activated CD4+ T cells in Peripheral Blood Mononuclear Cells.
Japan |
Male/Female adults
Adult |
Others
NO
To examine the effect of immunity index of peripheral blood CD4+ T cells by the intake of a fermented milk drink containing lactic acid bacteria.
Safety,Efficacy
Expression of activation markers on activated CD4+ T cells
1. Immune cell composition of Peripheral Blood Mononuclear Cells.
2. Immune-related markers in plasma.
3. Immune-related markers in feces.
4. Metabolites in feces.
5. Background questionnaire on daily life
6. Daily questionnaire on test drink and health condition.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Food |
Consumption of a fermented milk drink (1 bottle a day) for 8 weeks.
20 | years-old | <= |
60 | years-old | >= |
Male and Female
1. Males and females aged 20 to below 60 years at the time of consent acquisition.
2. Subjects who can give informed consent to partake in this study, after being provided with an explanation of the protocol detail.
1. Subjects who experience abdominal symptoms (such as diarrhea, abdominal pain, bloating) upon consumption of dairy products.
2. Subjects who regularly use Food for Specified Health Uses (FOSHU), Foods with Function Claims, or health food (including supplements) more than twice a week, which may potentially affect the study and cannot discontinue them from the time of consent acquisition.
3. Subjects who are taking medications (such as antibiotics, Intestinal preparations, laxatives) more than twice a week, which may potentially affect the trial, and cannot restrict their use during the study period.
4. Subjects who excessive alcohol intake.
5. Subjects who smoke heavily (not less than 21 cigarettes a day)
6. Females who are pregnant or lactating, and females who could become pregnant or lactating during test period.
10
1st name | Tomoaki |
Middle name | |
Last name | Naito |
Yakult Honsha Co., Ltd.
Yakult Central Institute
186-8650
5-11 Izumi, Kunitachi-shi, Tokyo, Japan
042-577-8920
tomoaki-naito@yakult.co.jp
1st name | Tomoaki |
Middle name | |
Last name | Naito |
Yakult Honsha Co., Ltd.
Yakult Central Institute
186-8650
5-11 Izumi, Kunitachi-shi, Tokyo, Japan
042-577-8920
tomoaki-naito@yakult.co.jp
Yakult Honsha Co., Ltd.
None
Self funding
Shiba Palace Clinic Ethics Review Committee
DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, Japan
03-5408-1599
shiba_palace@s-palace-clinic.com
NO
2024 | Year | 02 | Month | 06 | Day |
Partially published
10
Completed
2024 | Year | 01 | Month | 18 | Day |
2024 | Year | 01 | Month | 18 | Day |
2024 | Year | 01 | Month | 19 | Day |
2024 | Year | 04 | Month | 16 | Day |
2024 | Year | 10 | Month | 31 | Day |
2024 | Year | 12 | Month | 31 | Day |
2024 | Year | 02 | Month | 02 | Day |
2024 | Year | 08 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061087